started · updated
Halozyme and Argenx expand ENHANZE technology collaboration
Halozyme Therapeutics and Argenx have expanded their global collaboration and licensing agreement. Under the new terms, Argenx has gained exclusive access to Halozyme’s ENHANZE drug-delivery technology for two additional therapeutic targets, increasing the total number of licensed targets from six to eight.
The ENHANZE platform utilizes recombinant human hyaluronidase (rHuPH20) to increase the permeability of subcutaneous tissue. This allows drugs that typically require long intravenous infusions to be administered via subcutaneous injection, enhancing patient convenience. The partnership follows the successful development of VYVGART Hytrulo, a subcutaneous formulation of the FcRn-targeting antibody efgartigimod alfa, which has received regulatory approvals for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
While the specific targets and financial details, including upfront payments and royalty rates, were not disclosed, Halozyme is eligible for milestone payments and royalties on net sales of products utilizing the technology. Halozyme’s ENHANZE technology is currently licensed to several major pharmaceutical companies, including Roche, Pfizer, and Eli Lilly.
Entities
Halozyme Therapeutics · Helen Torley · Vyvgart Hytrulo · argenx